Short Interest in Precipio, Inc. (NASDAQ:PRPO) Drops By 19.8%

Precipio, Inc. (NASDAQ:PRPO) saw a significant decline in short interest in August. As of August 15th, there was short interest totaling 7,300 shares, a decline of 19.8% from the July 31st total of 9,100 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 11,300 shares, the short-interest ratio is currently 0.6 days. Based on an average trading volume of 11,300 shares, the short-interest ratio is currently 0.6 days. Approximately 0.5% of the company’s stock are sold short.

Precipio Trading Down 0.2%

NASDAQ:PRPO opened at $21.20 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.93 and a quick ratio of 0.69. The firm has a 50-day moving average of $15.05 and a 200-day moving average of $10.37. The company has a market cap of $34.34 million, a PE ratio of -17.82 and a beta of 1.09. Precipio has a one year low of $3.90 and a one year high of $22.38.

Precipio (NASDAQ:PRPO) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported $0.05 EPS for the quarter. The company had revenue of $5.65 million during the quarter. Precipio had a negative net margin of 8.48% and a negative return on equity of 15.00%.

Institutional Investors Weigh In On Precipio

An institutional investor recently bought a new position in Precipio stock. AMH Equity Ltd acquired a new position in Precipio, Inc. (NASDAQ:PRPO) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 38,294 shares of the biotechnology company’s stock, valued at approximately $240,000. AMH Equity Ltd owned approximately 2.55% of Precipio as of its most recent filing with the Securities and Exchange Commission. 10.45% of the stock is owned by hedge funds and other institutional investors.

Precipio Company Profile

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.